93 related articles for article (PubMed ID: 3203969)
1. Enhanced murine respiratory tract IgA antibody response to oral influenza vaccine when combined with a lipoidal amine (avridine).
Bergmann KC; Waldman RH
Int Arch Allergy Appl Immunol; 1988; 87(3):334-5. PubMed ID: 3203969
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of antibody response of turkeys to trivalent avian influenza vaccine by positively charged liposomal avridine adjuvant.
Fatunmbi OO; Newman JA; Sivanandan V; Halvorson DA
Vaccine; 1992; 10(9):623-6. PubMed ID: 1502840
[TBL] [Abstract][Full Text] [Related]
3. Studies on anti-viral mucosal immunity with the lipoidal amine adjuvant avridine.
Anderson AO; Wood OL; King AD; Stephenson EH
Adv Exp Med Biol; 1987; 216B():1781-90. PubMed ID: 3425462
[No Abstract] [Full Text] [Related]
4. Enhanced mucosal priming by cholera toxin and procholeragenoid with a lipoidal amine adjuvant (avridine) delivered in liposomes.
Pierce NF; Sacci JB
Infect Immun; 1984 May; 44(2):469-73. PubMed ID: 6370867
[TBL] [Abstract][Full Text] [Related]
5. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines.
Asahi Y; Yoshikawa T; Watanabe I; Iwasaki T; Hasegawa H; Sato Y; Shimada S; Nanno M; Matsuoka Y; Ohwaki M; Iwakura Y; Suzuki Y; Aizawa C; Sata T; Kurata T; Tamura S
J Immunol; 2002 Mar; 168(6):2930-8. PubMed ID: 11884464
[TBL] [Abstract][Full Text] [Related]
6. Antibody responses and protection in mice immunized orally against influenza virus.
Takase H; Murakami Y; Endo A; Ikeuchi T
Vaccine; 1996 Dec; 14(17-18):1651-6. PubMed ID: 9032895
[TBL] [Abstract][Full Text] [Related]
7. Oral adjuvant activity for nasal influenza vaccines caused by combination of two trihydroxy fatty acid stereoisomers from the tuber of Pinellia ternata.
Nagai T; Shimizu Y; Shirahata T; Sunazuka T; Kiyohara H; Omura S; Yamada H
Int Immunopharmacol; 2010 Jun; 10(6):655-61. PubMed ID: 20230917
[TBL] [Abstract][Full Text] [Related]
8. Combined oral/nasal immunization protects mice from Sendai virus infection.
Nedrud JG; Liang XP; Hague N; Lamm ME
J Immunol; 1987 Nov; 139(10):3484-92. PubMed ID: 2824609
[TBL] [Abstract][Full Text] [Related]
9. A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.
Neuhaus V; Chichester JA; Ebensen T; Schwarz K; Hartman CE; Shoji Y; Guzmán CA; Yusibov V; Sewald K; Braun A
Vaccine; 2014 May; 32(26):3216-22. PubMed ID: 24731807
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of monophosphoryl lipid A as adjuvant for pulmonary delivered influenza vaccine.
Patil HP; Murugappan S; ter Veer W; Meijerhof T; de Haan A; Frijlink HW; Wilschut J; Hinrichs WL; Huckriede A
J Control Release; 2014 Jan; 174():51-62. PubMed ID: 24269505
[TBL] [Abstract][Full Text] [Related]
11. Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination.
Hirabayashi Y; Kurata H; Funato H; Nagamine T; Aizawa C; Tamura S; Shimada K; Kurata T
Vaccine; 1990 Jun; 8(3):243-8. PubMed ID: 2363302
[TBL] [Abstract][Full Text] [Related]
12. Use of recombinant flagellin in oil-in-water emulsions enhances hemagglutinin-specific mucosal IgA production and IL-17 secreting T cells against H5N1 avian influenza virus infection.
Lai CH; Tang N; Jan JT; Huang MH; Lu CY; Chiang BL; Huang LM; Wu SC
Vaccine; 2015 Aug; 33(35):4321-9. PubMed ID: 25858857
[TBL] [Abstract][Full Text] [Related]
13. Immune responses and protection in different strains of aged mice immunized intranasally with an adjuvant-combined influenza vaccine.
Asanuma H; Hirokawa K; Uchiyama M; Suzuki Y; Aizawa C; Kurata T; Sata T; Tamura S
Vaccine; 2001 Jul; 19(28-29):3981-9. PubMed ID: 11427274
[TBL] [Abstract][Full Text] [Related]
14. Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
Tamura S; Ainai A; Suzuki T; Kurata T; Hasegawa H
Jpn J Infect Dis; 2016; 69(3):165-79. PubMed ID: 27212584
[TBL] [Abstract][Full Text] [Related]
15. Mannan adjuvants intranasally administered inactivated influenza virus in mice rendering low doses inductive of strong serum IgG and IgA in the lung.
Proudfoot O; Esparon S; Tang CK; Laurie K; Barr I; Pietersz G
BMC Infect Dis; 2015 Feb; 15():101. PubMed ID: 25887952
[TBL] [Abstract][Full Text] [Related]
16. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
[TBL] [Abstract][Full Text] [Related]
17. Consecutive inoculations of influenza virus vaccine and poly(I:C) protects mice against homologous and heterologous virus challenge.
Moriyama M; Chino S; Ichinohe T
Vaccine; 2017 Feb; 35(7):1001-1007. PubMed ID: 28111142
[TBL] [Abstract][Full Text] [Related]
18. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E
Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of avridine as an adjuvant for Newcastle disease virus antigen in chickens.
Rweyemamu MM; Umehara O; de Lucca-Neto D; Baltazar MC; Vicente FE; Medeiros-Neto Rda R
Am J Vet Res; 1986 Jun; 47(6):1243-8. PubMed ID: 3729124
[TBL] [Abstract][Full Text] [Related]
20. Nasal vaccination with r4M2e.HSP70c antigen encapsulated into N-trimethyl chitosan (TMC) nanoparticulate systems: Preparation and immunogenicity in a mouse model.
Dabaghian M; Latifi AM; Tebianian M; NajmiNejad H; Ebrahimi SM
Vaccine; 2018 May; 36(20):2886-2895. PubMed ID: 29627234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
